Specialty Generics Market Report, Size, Share, Trends and Forecast to 2024

NEW YORK - Aug. 5, 2019 - PRLog -- The global specialty generics market is being driven by the ongoing R&D activities to formulate specialty generics with improved efficacy and affordable prices.

According to the latest report by IMARC Group, titled "Specialty Generics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024", the global specialty generics market size reached US$ 44.8 Billion in 2018. Specialty generics refer to off-patented drugs which are used to target chronic or complex health conditions. These drugs require special handling, monitoring or administration and generally need prior authorization to order them. Nowadays, specialty generics are gaining immense popularity as they are utilized to treat rare chronic diseases such as cancer, HIV AIDS, rheumatoid arthritis and hemophilia

Global Specialty Generics Market Trends:

The increasing demand for specialty drugs has encouraged the governments of various countries to regulate and provide supporting policies for the production of specialty generics. Besides this, unlike newly patented specialty drugs, specialty generics are less expensive to develop and manufacture as they do not have to undergo any clinical trials and approval before entering the market. As a result, these products involve low risk and high margins as compared to newly patented drugs which usually take three to four years for product development and approval. Moreover, manufacturers are involved in research and development (R&D) to create new and innovative specialty drug formulations that are more efficient and cost-effective as compared to their branded counterparts. Additionally, several companies are engaging in mergers and acquisitions (M&A) to expand their specialty generics capacities. For instance, Alvogen, a pharmaceutical company, acquired County Line Pharmaceuticals that is involved in the development of specialty generics. Looking forward, the market value is projected to reach US$ 88.9 Billion by 2024, exhibiting a CAGR of 11.9% during 2019-2024.

Insights on Market Segmentation:

Breakup by Route of Administration

1. Injectable

2. Oral

3. Others

Breakup by Indication

1. Oncology

2. Autoimmune Diseases

3. Infectious Diseases

4. Others

Request for a sample copy of this report: https://www.imarcgroup.com/specialty-generics-market/requestsample

Breakup by Distribution Channel

1. Retail Pharmacies

2. Specialty Pharmacies

3. Hospital Pharmacies

Breakup by Region

1. North America

2. Europe

3. Asia Pacific

4. Latin America

5. Middle East and Africa

Browse full report with detailed TOC and list of figures and tables: https://www.imarcgroup.com/specialty-generics-market

Competitive Landscape

The competitive landscape of the market has also been examined with some of the key players being Teva Pharmaceuticals Industries, Akorn, Inc., Mylan N.V., Mallinckrodt, Sandoz International GmbH, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Valeant Pharmaceuticals, Apotex Corp., Endo International plc.